Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.
Identifieur interne : 001917 ( PubMed/Corpus ); précédent : 001916; suivant : 001918Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.
Auteurs : Joseph R. Calabrese ; Maurizio Fava ; George Garibaldi ; Heinz Grunze ; Andrew D. Krystal ; Thomas Laughren ; Wayne Macfadden ; Robert Marin ; Andrew A. Nierenberg ; Mauricio TohenSource :
- Journal of affective disorders [ 1573-2517 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antidepressive Agents, Antipsychotic Agents.
- psychology : Bipolar Disorder, Depressive Disorder, Major.
- Apathy, Humans, Motivation, Research Design.
Abstract
There is growing research interest in studying motivational deficits in different neuropsychiatric disorders because these symptoms appear to be more common than originally reported and negatively impact long-term functional outcomes. However, there is considerable ambiguity in the terminology used to describe motivational deficits in the scientific literature. For the purposes of this manuscript, the term "amotivation" will be utilised in the context of mood disorders, since this is considered a more inclusive/appropriate term for this patient population. Other challenges impacting the study of amotivation in mood disorders, include: appropriate patient population selection; managing or controlling for potential confounding factors; the lack of gold-standard diagnostic criteria and assessment scales; and determination of the most appropriate study duration.
DOI: 10.1016/j.jad.2014.06.056
PubMed: 25113957
Links to Exploration step
pubmed:25113957Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.</title><author><name sortKey="Calabrese, Joseph R" sort="Calabrese, Joseph R" uniqKey="Calabrese J" first="Joseph R" last="Calabrese">Joseph R. Calabrese</name><affiliation><nlm:affiliation>University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Bipolar Disorders Research Center, 10524 Euclid Avenue, 12th Floor, Cleveland, Ohio 44106, USA. Electronic address: Joseph.Calabrese@UHhospitals.org.</nlm:affiliation></affiliation></author><author><name sortKey="Fava, Maurizio" sort="Fava, Maurizio" uniqKey="Fava M" first="Maurizio" last="Fava">Maurizio Fava</name><affiliation><nlm:affiliation>Massachusetts General Hospital, Boston, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Garibaldi, George" sort="Garibaldi, George" uniqKey="Garibaldi G" first="George" last="Garibaldi">George Garibaldi</name><affiliation><nlm:affiliation>F. Hoffman-La Roche AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Grunze, Heinz" sort="Grunze, Heinz" uniqKey="Grunze H" first="Heinz" last="Grunze">Heinz Grunze</name><affiliation><nlm:affiliation>Newcastle University, Tyne & Wear, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Krystal, Andrew D" sort="Krystal, Andrew D" uniqKey="Krystal A" first="Andrew D" last="Krystal">Andrew D. Krystal</name><affiliation><nlm:affiliation>Duke University School of Medicine, Durham, N.C., USA.</nlm:affiliation></affiliation></author><author><name sortKey="Laughren, Thomas" sort="Laughren, Thomas" uniqKey="Laughren T" first="Thomas" last="Laughren">Thomas Laughren</name><affiliation><nlm:affiliation>Laughren Psychopharm Consulting, Rockville, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Macfadden, Wayne" sort="Macfadden, Wayne" uniqKey="Macfadden W" first="Wayne" last="Macfadden">Wayne Macfadden</name><affiliation><nlm:affiliation>F. Hoffman-La Roche AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Marin, Robert" sort="Marin, Robert" uniqKey="Marin R" first="Robert" last="Marin">Robert Marin</name><affiliation><nlm:affiliation>University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nierenberg, Andrew A" sort="Nierenberg, Andrew A" uniqKey="Nierenberg A" first="Andrew A" last="Nierenberg">Andrew A. Nierenberg</name><affiliation><nlm:affiliation>Massachusetts General Hospital, Boston, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tohen, Mauricio" sort="Tohen, Mauricio" uniqKey="Tohen M" first="Mauricio" last="Tohen">Mauricio Tohen</name><affiliation><nlm:affiliation>University of New Mexico, Albuquerque, NM, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25113957</idno><idno type="pmid">25113957</idno><idno type="doi">10.1016/j.jad.2014.06.056</idno><idno type="wicri:Area/PubMed/Corpus">001917</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001917</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.</title><author><name sortKey="Calabrese, Joseph R" sort="Calabrese, Joseph R" uniqKey="Calabrese J" first="Joseph R" last="Calabrese">Joseph R. Calabrese</name><affiliation><nlm:affiliation>University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Bipolar Disorders Research Center, 10524 Euclid Avenue, 12th Floor, Cleveland, Ohio 44106, USA. Electronic address: Joseph.Calabrese@UHhospitals.org.</nlm:affiliation></affiliation></author><author><name sortKey="Fava, Maurizio" sort="Fava, Maurizio" uniqKey="Fava M" first="Maurizio" last="Fava">Maurizio Fava</name><affiliation><nlm:affiliation>Massachusetts General Hospital, Boston, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Garibaldi, George" sort="Garibaldi, George" uniqKey="Garibaldi G" first="George" last="Garibaldi">George Garibaldi</name><affiliation><nlm:affiliation>F. Hoffman-La Roche AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Grunze, Heinz" sort="Grunze, Heinz" uniqKey="Grunze H" first="Heinz" last="Grunze">Heinz Grunze</name><affiliation><nlm:affiliation>Newcastle University, Tyne & Wear, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Krystal, Andrew D" sort="Krystal, Andrew D" uniqKey="Krystal A" first="Andrew D" last="Krystal">Andrew D. Krystal</name><affiliation><nlm:affiliation>Duke University School of Medicine, Durham, N.C., USA.</nlm:affiliation></affiliation></author><author><name sortKey="Laughren, Thomas" sort="Laughren, Thomas" uniqKey="Laughren T" first="Thomas" last="Laughren">Thomas Laughren</name><affiliation><nlm:affiliation>Laughren Psychopharm Consulting, Rockville, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Macfadden, Wayne" sort="Macfadden, Wayne" uniqKey="Macfadden W" first="Wayne" last="Macfadden">Wayne Macfadden</name><affiliation><nlm:affiliation>F. Hoffman-La Roche AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Marin, Robert" sort="Marin, Robert" uniqKey="Marin R" first="Robert" last="Marin">Robert Marin</name><affiliation><nlm:affiliation>University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nierenberg, Andrew A" sort="Nierenberg, Andrew A" uniqKey="Nierenberg A" first="Andrew A" last="Nierenberg">Andrew A. Nierenberg</name><affiliation><nlm:affiliation>Massachusetts General Hospital, Boston, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tohen, Mauricio" sort="Tohen, Mauricio" uniqKey="Tohen M" first="Mauricio" last="Tohen">Mauricio Tohen</name><affiliation><nlm:affiliation>University of New Mexico, Albuquerque, NM, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of affective disorders</title><idno type="eISSN">1573-2517</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressive Agents (therapeutic use)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Apathy</term><term>Bipolar Disorder (psychology)</term><term>Depressive Disorder, Major (psychology)</term><term>Humans</term><term>Motivation</term><term>Research Design</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Bipolar Disorder</term><term>Depressive Disorder, Major</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Apathy</term><term>Humans</term><term>Motivation</term><term>Research Design</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is growing research interest in studying motivational deficits in different neuropsychiatric disorders because these symptoms appear to be more common than originally reported and negatively impact long-term functional outcomes. However, there is considerable ambiguity in the terminology used to describe motivational deficits in the scientific literature. For the purposes of this manuscript, the term "amotivation" will be utilised in the context of mood disorders, since this is considered a more inclusive/appropriate term for this patient population. Other challenges impacting the study of amotivation in mood disorders, include: appropriate patient population selection; managing or controlling for potential confounding factors; the lack of gold-standard diagnostic criteria and assessment scales; and determination of the most appropriate study duration.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25113957</PMID><DateCreated><Year>2014</Year><Month>08</Month><Day>26</Day></DateCreated><DateCompleted><Year>2015</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2014</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.</ArticleTitle><Pagination><MedlinePgn>439-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2014.06.056</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(14)00433-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is growing research interest in studying motivational deficits in different neuropsychiatric disorders because these symptoms appear to be more common than originally reported and negatively impact long-term functional outcomes. However, there is considerable ambiguity in the terminology used to describe motivational deficits in the scientific literature. For the purposes of this manuscript, the term "amotivation" will be utilised in the context of mood disorders, since this is considered a more inclusive/appropriate term for this patient population. Other challenges impacting the study of amotivation in mood disorders, include: appropriate patient population selection; managing or controlling for potential confounding factors; the lack of gold-standard diagnostic criteria and assessment scales; and determination of the most appropriate study duration.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This paper summarises the search for a consensus by a group of experts in the optimal approach to studying amotivation in mood disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The consensus of this group is that amotivation in mood disorders is a legitimate therapeutic target, given the magnitude of the associated unmet needs, and that proof-of-concept studies should be conducted in order to facilitate subsequent larger investigations. The focus of this manuscript is to consider the study of amotivation, as a residual symptom of major depressive disorder (MDD) or bipolar depression (BD), following adequate treatment with a typical antidepressant or mood stabiliser/antipsychotic, respectively.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">There is a paucity of data studying amotivation in mood disorders. This manuscript provides general guidance on the most appropriate study design(s) and methodology to assess potential therapeutic options for the management of residual amotivation in mood disorders.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Bipolar Disorders Research Center, 10524 Euclid Avenue, 12th Floor, Cleveland, Ohio 44106, USA. Electronic address: Joseph.Calabrese@UHhospitals.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fava</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garibaldi</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>F. Hoffman-La Roche AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>Heinz</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Newcastle University, Tyne & Wear, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krystal</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Duke University School of Medicine, Durham, N.C., USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laughren</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laughren Psychopharm Consulting, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macfadden</LastName><ForeName>Wayne</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>F. Hoffman-La Roche AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of New Mexico, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057565" MajorTopicYN="Y">Apathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amotivation</Keyword><Keyword MajorTopicYN="N">Apathy</Keyword><Keyword MajorTopicYN="N">Mood disorders</Keyword><Keyword MajorTopicYN="N">Motivational deficits</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>06</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25113957</ArticleId><ArticleId IdType="pii">S0165-0327(14)00433-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2014.06.056</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001917 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001917 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25113957
|texte= Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25113957" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |